NASDAQ$SMLR
Semler Scientific Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Semler Scientific's financial performance was affected by the ongoing COVID-19 pandemic, but showed signs of recovery towards the end of the quarter as restrictions eased.
Semler Scientific reported its Q2 2020 financial results, which were impacted by the COVID-19 pandemic. However, the company saw a recovery towards the end of the quarter as state governments eased restrictions. Variable fee license revenues increased in June compared to May, and preliminary results for July indicate further growth.
- The financial performance of the company continued to be affected by the ongoing COVID-19 pandemic.
- State governments began easing COVID-19 related executive orders towards the end of the reporting period.
- Test volumes decreased due to "social distancing" and other executive orders mandating "shelter-in-place" or similar restrictions.
- Operating expenses decreased during the second quarter of 2020 as a result of cost-cutting measures.
Headline financials
Revenue & EPS history
Semler Scientific · Revenue · Quarterly
$6.37M
Forward guidance
Semler Scientific does not provide formal guidance, but intends to manage its expenses and other costs in line with changes in revenues to conservatively preserve cash during these uncertain times. The company believes customer interest in its QuantaFlo® product and related services will return to, or exceed, pre-COVID-19 activity at such time as “shelter-in-place” or similar restrictions are lifted and non-emergency medical services resume.
Tailwinds
- The company intends to manage its expenses and other costs in line with changes in revenues.
- The company intends to conservatively preserve cash during these uncertain times.
- The company believes customer interest in its QuantaFlo® product and related services will return to, or exceed, pre-COVID-19 activity.
- The company expects activity to return when “shelter-in-place” or similar restrictions are lifted.
- The company expects activity to return when non-emergency medical services resume.
Headwinds
- The company's performance was affected by the ongoing COVID-19 pandemic.
- There remains some uncertainty as state and local governments continue to revise restrictions.
- Results in the first quarter and second quarter of 2020 are not indicative of any future quarter or the full fiscal year results.
- Test volumes decreased due to “social distancing” and other executive orders mandating “shelter-in-place” or similar restrictions.
- The company does not provide formal guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports
-0.2%
Avg return
Earnings day
-2.4%
Avg return
5 days after
-5.8%
Avg return
30 days after
54%
25 / 46 earnings
Positive
+33.6%
Q4 2014
Best reaction
-33.3%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | -10.7% | -16.0% | -25.1% | |
| Q2 2025 | -1.8% | +2.0% | -20.7% | |
| Q1 2025 | -11.4% | +17.9% | -19.3% | |
| Q4 2024 | +3.0% | -12.4% | -22.7% | |
| Q3 2024 | +27.1% | +29.9% | +106.6% | |
| Q2 2024 | -5.4% | -1.7% | -16.7% | |
| Q4 2023 | -32.7% | -36.8% | -42.5% | |
| Q3 2023 | +7.6% | — | — | |
| Q2 2023 | +7.9% | — | — | |
| Q1 2023 | +13.8% | — | — | |
| Q4 2022 | +26.9% | — | — | |
| Q3 2022 | -33.3% | — | — | |
| Q2 2022 | +19.4% | — | — | |
| Q1 2022 | -20.6% | — | — | |
| Q4 2021 | -27.3% | — | — | |
| Q3 2021 | -25.6% | — | — | |
| Q2 2021 | -2.7% | — | — | |
| Q1 2021 | +1.5% | — | — | |
| Q4 2020 | +13.6% | — | — | |
| Q3 2020 | +10.0% | — | — | |
| Q2 2020 | -3.6% | — | — | |
| Q1 2020 | -2.6% | — | — | |
| Q4 2019 | +1.8% | — | — | |
| Q3 2019 | +1.7% | — | — | |
| Q2 2019 | +1.5% | — | — | |
| Q1 2019 | -2.7% | — | — | |
| Q4 2018 | +4.8% | — | — | |
| Q3 2018 | -12.5% | — | — | |
| Q2 2018 | +20.6% | — | — | |
| Q1 2018 | +6.4% | — | — | |
| Q4 2017 | +2.5% | — | — | |
| Q3 2017 | +16.0% | — | — | |
| Q2 2017 | -5.9% | — | — | |
| Q1 2017 | +1.5% | — | — | |
| Q4 2016 | +7.9% | — | — | |
| Q3 2016 | -16.0% | — | — | |
| Q2 2016 | +8.1% | — | — | |
| Q1 2016 | -9.2% | — | — | |
| Q4 2015 | -7.9% | — | — | |
| Q3 2015 | +0.1% | — | — | |
| Q2 2015 | -12.2% | — | — | |
| Q1 2013 | +0.9% | — | — | |
| Q4 2014 | +33.6% | — | — | |
| Q3 2014 | -3.7% | — | — | |
| Q2 2014 | -2.0% | — | — | |
| Q1 2014 | +1.2% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro